,concept,cluster
1793,cardiac rhythm disorders,348
1946,cardiac rhythm disorder at baseline yes,348
1759,average maximum cimt ( mm ),347
1992,average of maximum far wall cimt ( mm ),347
1947,left circumflex coronary artery,346
1691,left circumflex artery,346
1926,mean bdi focal score ( sd ),345
1576,mean score on dasnmbr - nmbr ( crp ) ^,345
1565,thrombophilia,344
1760,thrombophilia  no . ( % ) e,344
1732,ncep risk category at study entry  n ( % ),343
1523,risk score category ( points ),343
1622,timi risk score nmbr - nmbr,343
1948,risk category ( points ),343
1818,acr deciles,342
1514,acr  mg / mmol,342
1463,enalapril,341
1585,enalapril + aliskiren dm = nmbr non - dm = nmbr,341
1456,high risk with atherosclerotic vascular disease *,340
1883,high - risk cvd  n ( % ),340
1874,high risk,340
1837,d - dimer level  mean ( sd )  ng / mld,339
1450,d - dimer levelsatinclusion,339
1562,emotional status,338
1446,emotional role,338
1428,comparison with placebo ( mean,337
1685,comparison with baseline ( mean,337
1426,ace inhibitors or angiotensin ii,336
1656,ace inhibitors or angiotensin ii blockers,336
1636,omega - nmbr fatty acid,335
1417,omega - nmbr fatty acid ( n = nmbr ),335
1639,former or never,334
1409,former n z nmbr,334
1640,type nmbr diabetes duration  years,333
1526,type nmbr diabetes,333
1398,type nmbr diabetes duration  mean ( sd )  years,333
1666,conventional treatment ( n = nmbr ),332
1393,conventional treatment,332
1351,ivabradine ( n = nmbr ),331
1684,ivabradine group,331
1641,ccv history / condition,330
1350,ccv history / condition at baseline,330
1771,physician global assessment of disease activity ( vas nmbr - nmbr mm ),329
1327,physician global assessment ( nmbr - nmbr mm vas ),329
1657,physician ' s global assessment of dis -,329
1822,other dmard use,328
1323,dmard | |,328
1623,chronic obstructive pulmonary disease  n ( % ),327
1317,chronic obstructive pulmonary disease,327
1312,thienopyridine drug at start of open - label period,326
1996,thienopyridine type,326
1579,aortic stenosis,325
1285,aortic stenosis  n ( % ),325
1265,bl updrs : high,324
1694,bl updrs : low,324
1542,rf positive  n ( % ),323
1532,rf and acpa negativenmbr,323
1256,rf positive  %,323
1246,planned thienopyridine at baseline,322
1356,planned valve surgery  n ( % ),322
1271,therapy ( asa nmbr / placebo nmbr ),321
1447,antithrombotic therapy,321
1243,therapy ( asa nmbr  nmbr / placebo nmbr ),321
1672,therapy at discharge,321
1224,yes  non - insulin - treated,320
1651,yes  insulin - treated,320
1216,coronary heart disease ( % ),319
1293,coronary heart disease,319
1495,seropositive ( rf + ve and / or acpa + ve ) subgroup,318
1212,seropositivity,318
1204,rosuvastatin of patients ( rate ),317
1250,rosuvastatin n = nmbr,317
1319,homa - ir  median ( qnmbr  qnmbr ),316
1189,bdmard - ir,316
1757,hypertension serum lipid values,315
1187,hypertension : no ( n = nmbr ),315
1475,hypertension and left ventricular hypertrophy,315
1180,infliximab - naive ( n = nmbr ),314
1547,infliximab nmbr mg / kg,314
1985,infliximab - experienced ( n = nmbr ),314
1727,endothelin - receptor antagonists,313
1177,endothelin - receptor antagonists plus phosphodiesterase type nmbr inhibitors,313
1161,saxagliptin nmbr . nmbr mg ( n = nmbr  nmbr ),312
1471,saxagliptin nmbrmg ( n z nmbr ),312
1916,saxagliptin nmbr mg ( n = nmbr  nmbr ),312
1159,tender joint count ( nmbr - nmbr ),311
1452,tender joint count  of nmbr,311
1142,dasnmbr - esr lda,310
1998,dasnmbr - esr remission,310
1130,calculated ldl - c in nmbr classes,309
1324,calculated ldl cholesterol ( week nmbr ),309
1564,concomitant therapy,308
1120,concomitant therapy  no . ( % ),308
1785,concomitant therapies n ( % ),308
1501,obesity  % *,307
1098,obesity ( body mass index > nmbr kg / mnmbr ),307
1097,usa and canada,306
1108,united states,306
1955,iwqol - lite total score ( arbitrary units ) #,305
1069,in ibdq total score at week nmbr  mean [se],305
1135,total score on the sgrq - c  i ,305
1607,native coronary - artery lesions,304
1064,native latin,304
1517,indication for stent,303
1062,indication for pci,303
1060,homa_ % b tx difference vs pbo  median change from baseline ( se ) nmbr,302
1080,homajr tx difference vs pbo  median change from baseline ( se ) nmbr lipid parameters,302
1257,sf - nmbr ( health transition score ),301
1053,sf - nmbr physical component summaryjj,301
1211,sf - nmbr score,301
1234,sf - nmbrvnmbr domain scores  mean [sd],301
1957,ls mean difference ( se ) vs placebo,300
1048,ls mean % change from baseline _ se,300
1476,ls mean ( s . e . ) primary endpoint : % change from baseline to week nmbr,300
1284,etanercept,299
1039,etanercept ( n = nmbr ),299
1683,ff / vi nmbr / nmbr pg od,298
1032,ff / vi nmbr / nmbr gg ( n = nmbr  nmbr ),298
1847,ff / vi nmbr mg / nmbr mg ( n = nmbr ),298
1870,ff nmbr pgod,298
1987,rivaroxaban ( n = nmbr ),297
989,rivaroxaban nmbr mg,297
1114,rivaroxaban + aspirin,297
1381,associated with connective tissue disease,296
1880,associated with corrected - congenital shunts,296
986,associated with hiv infection,296
1696,lipoprotein ( a ) tx difference vs pbo  ls mean % change from baseline ( se ),295
972,lipoprotein ( a ) ( mg / dl ),295
1342,lipoprotein ( a )  median ( ql  qnmbr )  nmol / l,295
965,proactive intervention ( n = nmbra ),294
1660,multivessel intervention  n ( % ),294
1029,copd - rosuvastatin ( n = nmbr ),293
962,copd or asthma,293
1067,copd severity : severe / very severe,293
988,copd severity ( gold stage ),293
1676,all ~ cause mort / hf hosp .,292
961,cause of heart failure,292
955,gold nmbr groups,291
1584,gold nmbr groups  n ( % ),291
968,history of hypercholesterolemia  n ( % ),290
932,history of hypercholesterolemia,290
1443,fenofibric acid + moderate - dose statin,289
930,rosuvastain + fenofibric acid nmbr = nmbr,289
926,presence of honeycombing  nmbr n ( % ),288
1734,presence of dactylitis  n ( % ),288
1000,presence of mets,288
1863,blood eosinophil,287
907,blood eosinophils count,287
902,st ( arc definite only ),286
1614,st change > nmbr mm,286
1968,simplified disease activity index score ( nmbr - nmbr ),285
900,simplified disease activity index,285
1534,percentage with disease duration < nmbr years,284
896,percentage difference ( nmbr % cl ),284
893,exenatide,283
1134,exenatide n = nmbr,283
884,ind / glynmbr / nmbr pg o . d . n = nmbr,282
1570,ind nmbr gg q . d . n / n ( % ),282
1665,ace - i / arb  ( % ),281
879,ace - i or arb use,281
1835,neither ace - i nor arb use,281
1914,rate ratio,280
863,rate / nmbr patient - years,280
1560,steroid use at baseline,279
855,steroid use at baseline  n ( % ),279
854,claudication ( fontaine class > nmbr ),278
1230,claudication,278
1936,claudication only,278
1418,pulmonary rales  n ( % ),277
851,pulmonary rales,277
842,carotid,276
1088,carotid revascularization,276
1483,native hawaiian / other,275
1432,native hawaiian or other pacific islander,275
836,hawaiian / pacific,275
828,secondary ( change in total updrs score from baseline to final visit in phase nmbr ),274
1802,secondary # nmbr,274
817,fc - ldl - c  friedewald - calculated,273
1487,fc - ldl - c  mg / dl,273
1755,no ascvd + additional cv risk factors  n ( % ),272
814,ascvd including tia,272
808,time of symptom onset to balloon inflation ( hrs ),271
1745,time of symptom onset to randomization ( hrs ),271
1406,history of second prior mi,270
1492,history of amputation,270
1836,history of vte * *,270
1329,history of major bleeding,270
1796,history of macroalbuminuriat  n ( % ),270
807,history of symptomatic,270
1550,history of chronic hf,270
1731,history of dyspepsia,270
1667,history of coronary revascularization,270
1307,alt  ast  or both > nmbrx uln,269
805,alt and / or ast > nmbr times uln consecutive #,269
804,low risk and fewer symptoms ( group a ),268
1873,low risk and more symptoms ( group b ),268
798,medical conditions  no . ( % ),267
1355,medical characteristics,267
797,exercise times per week  ( minimum,266
1430,exercise,266
1942,high on - treatment platelet reactivity *,265
791,high potencyc,265
1459,high ( > nmbr ) ( n = nmbr  nmbr  nmbr % ),265
977,high subgroup,265
1797,high ( > nmbr risk factor ),265
1030,abatacept / open - label abatacept,264
789,abatacept monotherapy ( n = nmbr ),264
1569,abatacept ( n = nmbr * ),264
788,ethnic origin  n ( % ),263
1415,ethnic origin,263
1125,fevi  l *,262
785,fevi  % predicted  mean ( sd ) nmbr,262
873,glyburide,261
784,glyburide ( n = nmbr ),261
782,exacerbations,260
1635,exacerbations in the previous year,260
767,potassium - sparing at last follow - up,259
1044,potassium,259
1943,potassium ( meql )  mean + sd  available for nmbr patients,259
1163,potassium - sparing at enrollment,259
766,qualifying mi type,258
1308,qualifying nstemi  n ( % ),258
1747,qualifying hbanmbrc ( % ),258
1093,history of cabg surgery,257
764,history of cabg surgery  n ( % ),257
1011,prior surgery : no,257
763,rec . ischemia leading to hasp,256
1618,rec . ischemia requiring revasc,256
1009,rec . ischemia due worsening angina,256
1671,active or previous cancer,255
762,active a,255
938,active cancer at randomization  n ( % ),255
756,angiography during index hospitalization,254
1924,angiographic data and treatment :,254
1054,angiographic data,254
1370,preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria,253
755,preoperative heart rate ( beats per minute ),253
1860,periprocedural anticoagulant,252
747,other anticoagulant,252
1951,creatinine clearance category  ml / min  no . ( % ) b,251
745,creatinine clearance at admission ( ml / min ),251
740,role physical,250
1772,role emotional,250
739,central / eastern europe / russia,249
1028,central / eastern europe and russia hr ( nmbr % cl ),249
801,revascularization,248
736,with revascularisation,248
735,patient ' s global assessment of disease activity  mean ( sd ),247
1200,patient global assessment of disease activity ( vas nmbr - nmbr mm ),247
1912,egfr ( ml / min / nmbr . nmbr mnmbr [mdrdequation] ),246
746,egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr  nmbr ),246
731,egfr  ml / min / mnmbr,246
846,egfr < nmbr ml / min / nmbr . nmbr mnmbr ( mdrd ),246
1828,egfr ( ml / min / nmbr - nmbr mz ),246
818,egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr ( nmbr . nmbr % ),246
861,egfr  ml min nmbr nmbr . nmbr m nmbr,246
1617,egfr < nmbr  n ( % ),246
1829,egfr ( mdrd )  ml / min / nmbr . nmbr mnmbr,246
1313,egfr ( mumin / nmbr . nmbr mnmbr ),246
1804,primary pci no .,245
1227,primary + gusto moderate or severe bleeding,245
1304,primary ep ( cvd / mi / ri ),245
1253,primary + gusto severe bleeding,245
726,primary pci ( n = nmbr ),245
1567,low - dose rivaroxaban plus aspirin ( n = nmbr ),244
1493,low - dose rivaroxaban + aspirin group,244
800,low - dose rivaroxaban + aspirin ( n / n ),244
721,low - dose aspirin use at baseline yes,244
1736,post - bronchodilator fevnmbr  reversibility percentage of baseline value,243
793,post - bronchodilator fvc ( l ) a,243
1382,postbronchodilator lung function at screening,243
984,post - bronchodilator fevnmbr ( % predicted * ),243
1871,fevnmbr post - bronchodilator  % predicted normal,243
719,post - bronchodilator reversibility fevnmbr ( % ) mean ( sd ),243
1139,history of currently treated hypertension  n ( % ),242
715,history of systemic hypertension,242
1371,glucose  mmol / l,241
700,glucose - lowering therapies,241
1695,fevnmbr % reversibility,240
1865,fevnmbr reversibility  pre - / post - albuterol  %,240
1235,reversibility ( bnmbr - agonist )  %  mean ( sd ) nmbr,240
698,reversibility of fevnmbr ( % ),240
696,selected clinical characteristics  n ( % ),239
702,selected baseline medications,239
1202,myocardial ischaemia,238
692,ischemic heart disease  %,238
1809,other ischaemic heart disease ( non - infarction ),238
1260,pnmbrynmbr inhibitor,237
691,pdenmbr inhibitor monotherapy,237
1777,adjusted change from baseline mean ( s . e . ),236
680,adjusted mean change from baseline ( nmbr % ci )  % [mmol / mol],236
957,vascular intervention,235
1431,vascular territory # nmbr,235
679,vascular disordersb,235
1864,short - acting bnmbr - agonists,234
666,short - acting anticholinergics,234
1557,laba / ics use at screening  n ( % ),233
816,laba + ics ( free or fixed - dose combination ),233
1586,ics  mg / day,233
1071,ics use at screening  n ( % ),233
665,laba + ics,233
1296,losartan + placebo,232
664,losartan n = nmbr,232
1553,sfc nmbr / nmbr mg twice daily ( n = nmbr ),231
662,sfc nmbr / nmbr | ig bid n = nmbr,231
730,calcium antagonists  n ( % ),230
661,ccbs  ( % ),230
660,outcome,229
1022,adverse outcome,229
655,partial mayo clinic scored,228
929,partial mayo score $ | |,228
844,low density lipoprotein cholesterol  mg / dl * *,227
1821,low density lipoprotein cholesterol - mg / dltt,227
653,low - density lipoprotein cholesterol  %,227
1238,low - density lipoprotein cholesterol  mg / dl,227
1288,diuretic drugs  n ( % ),226
647,diuretic agent,226
979,diuretic drugs,226
1387,diuretic drugs ( excluding antialdosterone ),226
646,hbanmbrc distribution,225
773,hbanmbrc distribution at baseline  n ( % ),225
637,index event asymptomatic or unconfirmed,224
944,index event  %,224
1045,difference ( tiotropium - placebo ) ml ( nmbr % ci ),223
1861,lsms difference ( nmbr % ci ) nmbr,223
632,difference from baselinea,223
915,difference vs placebo  % [nmbr % cl]  p,223
1705,difference ( a ) vs placebo ( nmbr % cl ),223
1026,any prior anti - tnf treatment failure,222
631,prior therapy with tnf antagonist  n ( % ),222
1273,isolated igt,221
623,isolated pulmonary embolism,221
1556,disease and quality - of - life scores,220
621,disease,220
1176,any disease,220
1728,nt - probnp  median ( iqr )  pg / ml,219
602,nt - probnp pg / mla ( iqr ),219
600,urinary albumin / creatinine ratio  median mg / g ( range ),218
916,urinary albumin - to - creatinine ratio^,218
1573,urine albumin - to - creatinine ratio,218
707,vorapaxar group ( n = nmbr ),217
592,vorapaxar placebo nmbr - yr %,217
913,vorapaxar n = nmbr,217
1276,vorapaxar placebo nmbr - yr . km % rate,217
1210,enoxaparin / vka,216
591,enoxaparin,216
604,diet plus pravastatin group ( n = nmbr ),215
588,diet + pravastatin ( n = nmbr ),215
587,multiple tnfi *,214
1006,multiple,214
1984,location of infarction,213
579,location of ml,213
1699,location of crohn ' s disease  %,213
577,fevnmbr / fvc ( post - albuterol ),212
683,fevnmbr / fvc  %  mean ( sd ) nmbr,212
1525,fevnmbr / fvc ( post salbutamol ),212
1237,fev  at baseline,212
574,odds ratio versus placebo ( nmbr % ci ),211
1132,odds ratio,211
1529,odds ratio adj ( nmbr % cl ),211
571,physical component,210
1765,physical and cognitive examination : ! :,210
564,arb at last follow - up,209
1203,arb at enrollment,209
1756,arb / ace,209
1219,severe hyperkalemiac,208
1859,severe or worse airflow limitation,208
1612,severe ( gold nmbr ),208
1477,severe n z nmbr,208
562,severe teaes,208
748,severe impairment ( < nmbr ),208
560,crohn ' s disease,207
1469,crohn ' s disease - related medication at baseline  n ( % ),207
559,mi type unknown ( % ),206
1449,mi or cad,206
558,selexipag,205
1497,selexipag ( n = nmbr ),205
551,tocilizumab,204
1703,tocilizumab ( n = nmbr ),204
543,ezetimibe nmbr mg + statin ( n = nmbr  nmbr ),203
888,ezetimibe,203
1708,ezetimibe use,203
535,glucocorticoids and immunosuppressants,202
1111,glucocorticoids plus immunosuppressive agents,202
522,neither glucocorticoids nor immunosuppressive agents,202
1470,post - menopausal ( a ),201
512,postmenopausal hormone use,201
914,postmenopausal  never or past hormone therapy use,201
1174,postmenopausal  current hormone,201
511,left anterior descending  n ( % ),200
542,left anterior descending,200
1283,n ( indacaterol nmbr ug / indacaterol nmbr ug / placebo ),199
506,n analysed,199
1680,p value for adjusted hr,198
1919,p value nmbr . nmbr,198
504,p value versus placebo,198
1857,p value ( on vs off omt ),198
1408,p value ( men versus women ),198
1020,discontinuations teaes,197
501,discontinuations,197
1673,north america hr ( nmbr % cl ),196
499,north america n z nmbr,196
1903,north america ( plus australia and new zealand ),196
498,anti - cholinergics ( short - acting ) a,195
1252,anti - cholinergics ( long - acting ),195
493,investigator - reported hypoglycaemia *,194
1988,investigator - determined myocardial infarction,194
492,serum pnmbrnp ( ^g / liter ),193
1845,serum ctx ( ng / ml ),193
1915,recurrent vte ( statin use vs non - use ),192
1746,recurrent heart failure,192
491,recurrent ischemia - urgent revascularization,192
479,region of enrollment  n ( % ) +,191
821,region of enrollment  no . ( % ),191
474,peri - or postmenopausal,190
1167,peri - op amiodarone : no ( n = nmbr ),190
472,tc / hdl - c ratio,189
1515,tc / hdl - c,189
597,ezetimibe / simvastatin nmbr / nmbr mg ( n = nmbr ),188
468,ezetimibe + simvastatin ( n = nmbr * ),188
1568,clinical criterianmbr,187
1763,any clinical ae,187
1546,clinical and laboratory measurements,187
467,clinical history,187
1925,clinical indication at the index procedure  n ( % ),187
457,biologic agents,186
1001,other biologic agent,186
765,western europe and other,185
456,western europe hr ( nmbr % cl ),185
1106,western europe and israel,185
919,cerebrovascular disorders  n ( % ),184
455,cerebrovascular disease  n ( % ),184
1413,data missing or no drug given,183
453,data missing,183
1749,three arm,182
1653,responders of three - item end point at nmbr weeks *,182
452,three or more drugs,182
1868,three of seven risk factors,182
1795,apolipoprotein b tx difference vs pbo  ls mean % change from baseline ( se ),181
450,apolipoprotein b^,181
904,sex  male / female  %,180
606,sex  n ( % ) male,180
1482,sex ( interaction : p = nmbr . nmbr ),180
449,sex : male ( n = nmbr ),180
448,hospitalized for asthma  n ( % ) *,179
1544,hospitalized for heart failure during that time period,179
1183,event / total,178
485,event rates  %,178
446,any event,178
813,moderate impairment ( nmbr to < nmbr ),177
445,moderate or less airflow limitation,177
1552,moderate teaes,177
1613,moderate thrombocytopenia ( < nmbrxnmbr / l ),177
794,moderate risk,177
1073,moderate or severe exacerbations in the previous year ( range ),177
1754,moderate ( gold nmbr ),177
1621,moderate ( nmbr risk factor ),177
444,amlodipine nmbrmg / v = nmbr,176
958,amlodipine / vaisartan ( n = nmbr ),176
441,cvd risk factors ( age > nmbr ),175
717,cardiovascular disease,175
1156,cvd or mi,175
1770,aliskiren,174
437,aliskiren ( n = nmbr ),174
1277,change from baseline  adjusted mean ( nmbr % ci )  %,173
774,change in haq - di ( mean ) t,173
436,change in mtss ( mean ),173
705,change in nt - probnp at nmbr months ( log - transformed ),173
1819,change at week nmbr,173
688,change in sbp ( nmbr months ),173
1035,change from baseline in hbanmbrc ( % ),173
1367,change from baseline in dasnmbr - esr  meannmbr sd,173
503,randomization to arterial sheath insertion,172
925,randomization groups nmbr and nmbr,172
1548,randomization - to -,172
935,asastoppedat randomization  n,172
584,randomisation visit ( baseline ),172
463,randomization to placebo or telmisartan,172
432,treatmentofpulmonary embolismpriorto randomization,172
1625,oral aminosalicylates,171
430,oral antidiabetes monotherapya  n ( % ),171
1806,oral blood glucose - lowering,171
490,oral agents use,171
1244,antihyperglycemic oral agent therapy,170
1197,hypoglycaemic agents,170
841,antihyperglycemic medication usage,170
427,antihyperglycemic,170
603,body mass index ( bmi )  kg / mnmbr,169
1133,body mass index  kg / mnmbr  median ( qnmbr  qnmbr ),169
426,body - mass index ( kg / mj ) previous diagnosis,169
1330,body - mass index  !  waist - to - hip ratio,169
1164,body mass index > nmbr kg / mnmbr  n ( % ),169
1714,neoplasia  n ( % ),168
423,neoplasia,168
1603,liraglutide ( n = nmbr  nmbr ),167
1144,liraglutide nmbr . nmbr mg / day ( n = nmbr ),167
418,liraglutide nmbr . nmbr mg ls means ( n ),167
416,bivariate frailty model ( statin users vs non - users ),166
1152,frailty status,166
409,psoriasis duration  yrs *,165
1798,psoriasis affecting > nmbr % of body - surface,165
892,psoriasis body surface area > nmbr %,165
406,final timi flow grade post - ppci,164
734,final timi flow,164
1722,ranolazine  n = inmbrinmbr,163
405,ranolazine ( n = nmbr  nmbr ),163
401,basal insulin analogue : insulin,162
1153,basal insulin dose at run - in ( u / day ),162
1975,individuals without diabetes  n = nmbr  nmbr,161
400,individuals with diabetes  n = nmbr,161
1758,measured at clinic visit with usual device,160
397,measured at home with automated device,160
391,nonaspirin antiplatelet agent,159
1920,nonaspirin antiplatelet,159
738,serum creatinine  limo nmbr nmbr,158
390,serum creatinine > nmbr mmol / l  n ( % ),158
1412,serum creatinine > nmbr pmol / l . n ( % ) |,158
1215,serum creatinine  mean ( sd )  pmol / l,158
959,week nmbr ( geometric mean  cv ),157
381,week nmbr ( itt population ),157
1468,week nmbr fpg  mean ( s . e . ),157
374,efficacy,156
534,efficacy and safety : net adverse clinical events *,156
960,triglycerides ( week nmbr ) a,155
1092,triglycerides > nmbr mg / dl,155
373,triglycerides  median ( range ),155
371,extended - duration enoxaparin  n / n ( % ),154
1878,extended - duration enoxaparin ( n = nmbr ),154
368,small - artery occlusion ( lacune ),153
413,small - artery occlusion,153
366,dose of aspirin,152
837,aspirin at any dose,152
1927,cabg during index hospitalization,151
1281,coronary artery bypass surgery,151
1662,cabg surgery,151
363,cabg or pci,151
1591,cabg > nmbr month ago,151
369,atorvastatin  n ( % ),150
360,atorvastatin dose,150
1322,atorvastatin ls means difference nmbr mg ( nmbr % ci ) a ( n = nmbr ),150
1768,drug discontinuation not due to death,149
359,drug - related teaesnmbr,149
357,events treatment ( nmbr ),148
1182,events  no .,148
484,ez / simva n = nmbr n ( % ),147
352,anmbr + ez n = nmbr,147
477,atrial fibrillation / flutter  n ( % ),146
351,atrial fibrillation / atrial flutter  %,146
1213,interval pain onset to admission,145
1816,interval from clopidogrel loading  h,145
350,interval study drug to pci,145
525,interval clopidogrel to pci,145
1533,hispanic,144
1993,hispanic ethnicity,144
340,hispanic ( n = nmbr ),144
442,former smoker ( n = nmbr ),143
338,former smoker  n ( % ),143
333,fatal and nonfatal ml,142
1664,fatal and nonfatal stroke,142
331,crp ( mg / dl ) < nmbr . nmbr,141
753,crp  mg / l : median ( range ),141
415,crp  nmol / l  median ( range ),141
839,crp ( mg / l ) : < nmbr,141
1663,crp concentration > nmbr . nmbr mg / dl ( nmbr mg / l )  n ( % ),141
1583,crp ( mg / l )  median ( min  max ),141
901,ratio of ldl to hdl,140
329,ratio fp / sal : sal ( nmbr % ci ),140
1986,time since first copd diagnosis ( years ),139
682,time since diagnosis of diabetesa  n ( % ),139
388,time from acs to randomization ( median  iqr ),139
328,time from symptoms to treatment,139
1554,time since diagnosis of type nmbr diabetes,139
354,time from qualifying event to randomization,139
1989,time from first eval,139
1972,time from randomization to pci ( non - st - elevation mi )  h,139
1357,time from randomization to pci ( st - elevation mi )  min,139
327,time of qualifying ecg to balloon inflation ( hrs ),139
322,left atrial diameter,138
1065,left atrial diameter  mm ( sd ),138
320,chd eze / simva ( n = nmbr],137
1442,chd + cerebral infarction,137
624,total cholesterol ( mg / dl )  mean + sd  available for nmbr patients,136
317,total cholesterol ( week nmbr ),136
572,indacaterol nmbr gg qd,135
921,indacaterol nmbr ug ( n = nmbr ),135
496,indacaterol nmbr ug versus indacaterol nmbr ug,135
316,indacaterol nmbr ug versus placebo,135
1057,indacaterol nmbr mg[n z nmbr],135
917,percent change,134
310,fevnmbr percent predicted ( sd ),134
634,never used lev,133
305,never / rarely,133
300,intravenous dobutamine,132
1170,intravenous anticoagulant during hospitalization,132
1361,v alsartan / hctz  n ( % ),131
298,hctz = hydrochlorothiazide . * based on wilcoxon nmbr - sample rank - sum tests for age and body mass index  t tests for systolic and diastolic blood and ' / nmbr tests for categorical variables . t data were missing for some patients .,131
1894,prehospital ticagrelor ( n = nmbr ),130
296,ticagrelor nmbr mg nmbr yr km %,130
1081,ticagrelor  nmbr mg ( n = nmbr ),130
898,ticagrelor nmbr mg vs . placebo hr ( nmbr % ci ),130
1902,ticagrelor nmbr mg nmbr year km ( % ),130
294,atrial fibrillation onset,129
1280,atrial fibrillation  n ( % ),129
286,no antidiabetic drug,128
311,antidiabetic medication | |,128
283,chf history,127
1909,congestive heart failure ( chf ) ( in past nmbr weeks ),127
768,congestive heart failure  n ( % ),127
1769,congestive heart failure ( < nmbr wk ),127
1952,chf on losartan ( % ),127
280,verapamil sr n = nmbr no . ( % ),126
614,verapamil sr n = nmbr,126
1898,symptom onset to hospital admission,125
268,symptom onset to start of reperfusion treatment : tenecteplase or arterial sheath insertion !,125
266,unstable angina ( biomarker negative ),124
1154,worsening angina,124
1712,eze / simva gender,123
1245,gender  % of patients,123
264,gender ( % ) male / female,123
1385,gender  women n  % ),123
1779,any established coronary artery disease,122
1049,established ascvd or > nmbr cv risk factors,122
263,established,122
1145,established ascvd,122
1394,left circumflex,121
261,left main artery,121
685,serum albumin  g / dl,120
258,serum albumin  g nmbr nmbr,120
251,combined trials,119
422,combined estimated gfr and albuminuria status,119
899,combined n = nmbr,119
992,combined end points,119
249,history of peripheral artery disease,118
922,history of peripheral arterial disease ( % ),118
1239,white : black : other,117
1628,white  n ( % ),117
244,white / european,117
1853,peripheral embolism,116
243,no peripheral revascularization ( n = nmbr  nmbr ),116
241,geometric mean crp concentration ( mg / l ),115
625,geometric mean of baseline,115
743,beta - blockers ( all )  n ( % ),114
582,beta - blocker at last follow - up |,114
240,beta - blocker ( except sotalol ),114
233,fibrinogen,113
1420,fibrinogen  g / l,113
1151,fibrinogen ( pmol / l ) c,113
231,normal ( egfr > nmbr ),112
275,normal / mild ckd,112
883,normal troponin,112
225,fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % ),111
897,fibrinolysis ( n = nmbr ),111
223,high - density lipoprotein cholesterol  mg / l,110
1171,high density lipoprotein cholesterol  mg / dl^,110
402,oral hypoglycemic drug,109
949,oral hypoglycemic agent,109
219,other oral hypoglycemic drug ( s ),109
1856,oral hypoglycemic drugs only,109
217,metabolic syndrome characteristics  n ( % ),108
856,metabolic syndrome ( > nmbr of nmbr characteristics ),108
1489,other glp - nmbr receptor agonist,107
215,glp - nmbr receptor agonist ( other than study drug ),107
737,antihypertensive medication or,106
214,antihypertensive  antianginal  and other cardiovascular medications,106
1587,antihypertensive drug  %,106
403,antihypertensive treatment,106
1513,laboratory values at randomization ( median and iqr ),105
208,laboratory values,105
1979,laboratory measures,105
1407,laboratory data  mean ( sd ),105
1503,laboratory data,105
206,standard ( n = nmbr ),104
1850,standard ( nmbr ),104
1815,standard care n ( % ),104
514,standard control ( n = nmbr ) no . of patients ( percent ),104
918,standard care ( n = nmbr ),104
205,no pah therapy,103
1774,pah classification,103
1013,smoking history  pack - years  mean ( sd ),102
204,smoking history ( ever ),102
1302,urgent cor revasc,101
200,urgent coronary revascularization,101
198,extent of disease  %,100
1388,extent of disease  n ( % ),100
196,czp nmbr mg ( n nmbr nmbr ),99
1150,czp nmbr mg  % ( n / n ),99
194,pre - bronchodilator fevnmbr / fvc ratio *,98
749,pre - bronchodilator fevnmbr ( % predicted normal ),98
563,any statin + other llt,97
1967,statin users ( n = nmbr ),97
1983,statin  n ( % ),97
809,statin potency stratum  n ( % ),97
481,statin + ezetimibe  n ( % ),97
1185,statin monotherapy,97
193,statin treatment,97
1530,no statin vs statin alone vs any statin plus other llt,97
783,statin ( open ),97
537,statin use at baseline,97
521,statin with niacin,97
1058,other statin,97
190,a mini - mental state examination  omega - nmbr fatty acids vs placebo,96
1521,mini - mental state examination,96
1811,a mini - mental state examination  insulin glargine vs standard care,96
189,risk reduction  %,95
594,risk reduction ( %  nmbr % ci ),95
1337,age at first seizure  years  mean ( sd ),94
269,age ( years ) [median ( nmbrth to nmbrth percentile ) ],94
633,age at randomization ( years ),94
336,age ( yrs ) < nmbr,94
1862,age  y sex  no . ( % ),94
971,age  mean years  [sd],94
722,age  yrs  median ( nmbrth  nmbrth ),94
1851,age  median ( interquartile range )  y,94
238,age [years] ( interaction : p = nmbr . nmbr ),94
1807,age nmbr + yrs,94
186,age ( years ) : nmbr - < nmbr,94
687,age at screening,94
1852,one or more copd exacerbations ( n / n [ % ] ),93
640,one or more blood pressure medications  n ( % ),93
181,one - third radius,93
178,ace inhibitor or arb at last follow - up,92
364,ace inhibitor monotherapy,92
1594,ace - inhibitor use,92
408,ace inhibitor or arb at enrollment,92
909,ace inhibitor at last follow - up,92
176,gfr ( mdrd ) ( ml / min / nmbr - nmbr mnmbr ),91
1838,gfr ( ml / min per nmbr . nmbr nr ),91
1027,pioglitazone pts / n ( % ),90
174,pioglitazone events / n ( % ),90
1465,initiation of dialysis  renal transplantation  or creatinine . nmbr . nmbr mg / dl ( nmbr mmol / l ),89
173,initiation of insulin,89
170,jsn score  mean nmbr sd,88
769,score distribution : < nmbr,88
1424,score > nmbr %  % of patients,88
1740,chanmbrdsnmbr - vasc score ( median  iqr ),88
583,rentrop score,88
168,smoking in the past year,87
192,smoking : ex - smoker,87
386,smoking ( a ),87
389,smoking pack - years,87
1335,smoking pack year ( years ) fl,87
1893,cardiovascular risk,86
890,cardiovascular inclusion criteriat,86
642,cardiovascular hospitalization,86
167,all cardiovascular,86
728,cardiovascular and respiratory,86
1939,treatment before admission ( % ),85
1360,randomised treatment,85
1652,epa treatment ( n = nmbr ),85
848,treatment with candesartan,85
164,treatment after admission,85
1318,treatment difference  ml,85
920,location of treatment center,85
254,fasting c - peptide  ng / ml,84
1050,fasting plasma glucose  mg / dl  mean ( sd ) b,84
163,fasting free fatty acids ( ^mol / liter ),84
878,fasting insulin,84
1876,fasting plasma glucose,84
1682,unknown,83
159,unknown type,83
1376,diabetes duration ( known )  % of patients,82
500,diabetes durationa < median,82
1840,diabetes duration  median ( iqr )  years,82
158,diabetes with target organ disease *,82
750,insulin + oad,81
1543,without insulin or insulin - modifying therapy,81
699,insulin ( pmol / l ) t vital signs,81
1085,insulin and oral hypoglycemic drugs,81
157,oad plus insulin,81
1384,insulin - na ' ive,81
1410,insulin : glucose ratio,81
151,dactylitis count,80
612,dactylitis count ( nmbr - nmbr )  mean ( sd ),80
1232,dactylitis  n ( % ),80
147,risk of bleeding,79
714,accp bleeding risk at inclusion  no . ( % ) f,79
145,iglar dose at randomization ( u / day ),78
1580,any dose reduction,78
1581,hazard ratio for event ( nmbr % ci ),77
143,hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr  nmbr . nmbr ),77
141,both ptca and cabg,76
780,ptca or pci,76
290,severity of airflow limitation ( gold nmbr - nmbr )  n ( % ),75
1817,severity of copd *  n ( % ),75
139,severity of copd  ( gold nmbr )  %,75
931,severity n ( % ),75
308,severity of hypertensionb,75
1935,severity of copd  airflow limitation  n ( % ),75
1953,comorbidities  %,74
1855,co - morbidities  a n ( % ),74
129,comorbidities other than diabetes,74
963,comorbid diseasesa diabetesb,74
1140,tg  mmol / l [mg / dl],73
128,tg < nmbr  hdl > nmbr ( n = nmbr ),73
126,primary end point  no . of events / total no . ( % ),72
216,primary renal endpoint or death,72
1675,primary end point kaplan - meier rate  %,72
125,peripheral arterial disease  n ( % ),71
1630,any peripheral arterial disease,71
1900,erosion score  mean nmbr sd,70
124,erosion score,70
1524,erosion score  median ( min  max ),70
123,randomized to receive beta carotene,69
549,all randomized patients ( range ),69
1872,randomized to active yitamin e,69
1485,randomized,69
213,randomized to aspirin use,69
703,aspirin - erdp ( n = nmbr  nmbr ),68
539,aspirin but no ppi,68
1372,aspirin + clopidogrel ( n = nmbr ) nmbr . nmbr,68
940,aspirin and ppi,68
236,aspirin and other antiplatelet,68
1435,aspirin group,68
570,aspirin at last follow - up,68
1629,aspirin / antiplatelet,68
122,aspirin / other antiplatelet agents  n ( % ),68
1036,aspirin group ( n = nmbr nmbr ) ( nmbr nmbr person years ),68
464,aspirin nmbr clopidogrel,68
1753,aspirin use ( > nmbr mg ),68
1455,aspirin only ( n = nmbr  nmbr ),68
282,stent length per lesion  mm,67
117,stent plus placebo,67
1559,screening % predicted fevnmbr,66
116,screening prebronchodilator fevnmbr  l,66
1157,screening bmi ( kg / mnmbr ),66
941,screening % reversibility fevnmbr,66
1590,stroke or pvd  ( % ),65
114,stroke ( vs tia ),65
1155,use of parenteral antithrombotic,64
112,use of ace inhibitor,64
580,use of hormone replacement therapy ( a ),64
392,use of concomitant lipid - modifying therapy,64
228,no use of nmbr - asa compounds,64
1086,use of ics,64
412,timi major bleeding,63
142,major cerebrovascular,63
110,major cvd /,63
1400,major bleeding ( statin use vs non - use ),63
1792,major coronary,63
1162,years [range],62
209,years  mean ( sd ),62
109,years since menopause,62
928,years since pah diagnosis,62
108,mild impairment ( nmbr to < nmbr ),61
1374,mild or moderate copd,61
1434,estimated glomerular filtration rate - ml / min  median ( iqr ) ',60
107,estimated glomerular filtration rate ( mdrd )  ml / min / nmbr . nmbrmnmbr,60
1190,estimated glomerular filtration rate,60
1932,concomitant asthma medications  n ( % ),59
859,concomitant lipid - lowering therapy  n ( % ),59
1929,concomitant drug treatment,59
1282,concomitant atorvastatin dose  mg,59
106,concomitant corticosteroid use  n ( % ),59
307,no concomitant cortcosteroid use,59
1321,concomitant mtx use  n ( % ),59
1738,concomitant drugs,59
1668,concomitant conventional dmard use,59
668,concomitant antihyperglycaemic drugs  n ( % ),59
105,mtx + non - mtx,58
676,mtx exposure ( mg / week ),58
1619,type of concomitant statin,57
104,type of mi ( % ),57
1110,any type  according to daily dose * *,57
1627,type of des,57
1263,atenolol strategy,56
398,atenolol *,56
103,atenolol n = nmbr,56
678,atenolol n = nmbr no . ( % ),56
138,blood pressure,55
102,blood pressure  mean ( sd ) [range]  mm hg,55
790,calcium channel antagonists  n ( % ),54
1437,calcium - channel blockers ( % ),54
100,calcium channel blockers  n ( % ),54
97,valsartan / hctz  n / n ( % ),53
1137,valsartan / hctz,53
1209,clopidogrel dose on / before pci,52
1658,clopidogrel no . of patients % ),52
751,clopidogrel ( n = nmbr ),52
95,clopidogrel ( n = nmbr  nmbr ),52
330,clopidogrel  ticlopidine  or prasugrel,52
557,clopidogrel / ticlopidine,52
1099,clopidogrel plus aspirin ( n = nmbr ),52
309,clopidogrel  %,52
1782,clopidogrel + aspirin ( n = nmbr ),52
90,ischemic cerebrovascular disease  n ( % ),51
911,ischemic aetiology  n ( % ),51
677,ischaemic  n ( % ),51
341,ischemic tvr,51
89,etoricoxib dose,50
1023,etoricoxib nmbr mg n = nmbr n ( % ),50
85,after bronchodilation,49
1349,before bronchodilation,49
1103,cardiovascular medications  %,48
84,cardiovascular medications,48
777,placebo mean ( n ),47
1609,placebo ls means ( n ),47
1195,placebo no . of events / total no . ( % ),47
1240,placebo estimated mean,47
1052,placebo secukinumab nmbr mg,47
1688,placebo ( dm - vs . dm + ),47
729,placebo  n ( rate ),47
1091,rerandomization to placebo ( n = nmbr ) f,47
1015,feno placebo ( lsm ),47
629,placebo no . / total ( % ),47
947,placebo + mtx,47
1491,placebo event rate ( n = nmbr )  %,47
847,placebo n = nmbr subjects,47
912,placebo nmbr year km ( % ),47
509,placebo plus aspirin,47
83,with placebo ( n nmbr nmbr ),47
1735,placebo every nmbr weeks ( n = nmbr ),47
1401,placebo secukinumab pooled,47
79,coenzyme qnmbr  ^g / ml #,46
378,all with coenzyme qnmbr ( n = nmbr  nmbr ),46
1184,pooled empagliflozin ( n = nmbr ),45
291,pooled simva,45
74,pooled simvastatin factorial studies,45
73,american indian or alaska,44
267,american indian or native alaskan,44
72,amiodarone  n ( % ),43
1395,amiodarone vs . placebo no . hazard ratio ( nmbr . nmbr % cl ),43
1191,amiodarone,43
1274,pasi < nmbr *,42
71,pasi score ! * *,42
1014,estimated gfr  ml min - nmbr nmbr . nmbr m - nmbr ( sd ) a,41
1440,estimated gfr  < nmbr ml min - nmbr nmbr . nmbr m - nmbr  n ( % ) a,41
70,estimated glomerular filtration,41
649,estimated gfr ( ml / min / nmbr . nmbr mnmbr ) ^ |,41
652,estimated * creatinine clearance < nmbr mlvmin  %,41
673,estimated creatinine clearance < nmbr ml / min *,41
1010,current ( nmbr + cigs / day ),40
68,current atrial fibrillation or flutter on ecg,40
1332,current tobacco abuse  n ( % ),40
939,current (  nmbr cigs / day ),40
1249,current / past,40
1593,current or previous atrial fibrillation,40
1784,current ( % ),40
1429,mean ( s . d . ) hbalc  %,39
64,mean lipid values  mg / dl,39
1087,mean hscrp  mg / l ( sd ),39
508,mean cdai score,39
459,mean bmi  kg / mnmbr ( s . d . ),39
1764,mean ( sd ) feno  ppb,39
1645,mean age ( years ) race,39
978,mean ( sd ) body mass index  kg / mnmbr,39
92,mean age ( years ) ( s . d . ),39
1076,mean ( sd ) crp  mg / l *,39
1386,mean ( sd ) swollen joint count *,39
1218,mean weight  kg ( sd ),39
1558,mean change in radiographic end points,39
1486,nmbrbaseline mean,39
120,mean prebronchodilator fevnmbr ( sd )  % predicted,39
1704,mean ( sd ) duration of smoking  pack years,39
628,mean annualized exacerbation rate,39
1359,mean ( sd ) dasnmbr - nmbr ( esr ) *,39
1101,mean fevnmbr  l ( sd ),39
1844,mean sd fpg  mg / dl,39
1254,mean age  years ( nmbr % ci ),39
1937,mean % predicted dlco * ( sd ),39
425,mean age  y  median ( range ),39
86,mean nmbrmwd *  m ( sd ),39
1913,mean bmi  kg / mnmbr,39
1540,mean eosinophil count  per ml,39
218,mean duration of disease  years,39
723,mean ( s . d . ) free pcsknmbr  ng / ml,39
1588,mean ( sd ) post - bronchodilator fevnmbr reversibility  %,39
874,mean ( sd ) extent of exposure  days,39
1602,mean ( sd ) number of albuterol per day  puff,39
199,mean ( nmbr % ci ) difference vs saxa + dapa + met,39
867,mean yearly decline,39
710,mean number of exacerbations ( per patient - year [nmbr % ci] ),39
1830,previous stroke  n ( % ),38
1390,previous hypertension,38
1578,previous oral glucose - lowering agents  % of patients,38
1783,previous metformin use  %,38
1742,previous major bleeding,38
155,previous percutaneous coronary intervention,38
277,previous medications  n ( % ),38
779,previous heart failure,38
776,previous deep - vein thrombosis or pulmonary embolism,38
153,previous dmards use  n ( % ),38
1794,previous ischemic stroke  n ( % ),38
556,previous stroke ortransient ischaemic attack ( % ),38
792,previous myocardial infarction ( % ),38
1848,previous anti - tnf therapy  n [ % ],38
63,previous hf hospitalization  n ( % ),38
1299,previous balloon angioplasty  n ( % ),38
152,previous disease :,38
1261,previous cardiovascular disease !,38
1124,previous copd treatment  n ( % ) *,38
1129,previous transient ischaemic attack / ischaemic stroke previous warfarin use,38
787,previous vascular disease,38
62,lipid - lowering medication ( % ),37
1042,other lipid - modifying drug use at study entry  n ( % ),37
471,other lipid parameters,37
732,lipid lowering medication use,37
1316,lipid profile,37
1693,disease duration  median ( range ) years,36
61,disease duration nmbr to bnmbr years ( n = nmbr ),36
407,duration of disease  median,36
1610,duration of disease  years,36
60,first mace,35
752,first - generation stentt,35
881,median ( qnmbr : qnmbr ) duration of insulin use  years,34
385,median albumin / creatinine ratio ( g / mg ),34
1762,median ( qnmbr : qnmbr ) lp ( a )  mg / dl,34
1193,median ( qnmbr : qnmbr ) tg - rich lipoprotein cholesterol,34
586,median serum periostin  ng / mla,34
1059,median ( iqr ) age  years,34
891,median duration of study - drug administration,34
420,median change  %,34
1339,median blood eosinophil count  cells per pla,34
1314,median ( sd )  mg / mmol,34
953,median ( days ),34
59,median total cholesterol  mmol / l,34
1325,median ( qnmbr : qnmbr ) total daily insulin dosenmbr,34
495,median ( qnmbr : qnmbr ) tgs,34
57,elevated hscrp > nmbr mg / l  n ( % ),33
995,elevated tg,33
201,caucasian simva,32
55,caucasian ethnicity,32
54,medical therapy only ( n = nmbr ),31
111,medical therapy ( n = nmbr ),31
49,ppi but no aspirin,30
487,nontrial ppi,30
303,ppi use ( p = nmbr - nmbrt ),30
567,multivessel pci,29
47,after pci,29
1928,pci for index event,29
1041,abx - facil . pci,29
1504,other drugs,28
46,drugs used in diabetes  n ( % ),28
148,cv medication  % of patients,27
45,cv death  ml  or stroke,27
1305,cv death / mi / stroke,27
1340,cv death or first hhf,27
657,cv risk factor,27
334,cv event  years,27
607,cv risk factor - no . ( % ),27
52,cv death + hf hospitalization,27
1882,baseline albumin : < nmbr,26
486,baseline nmbr - h ppg ,26
81,baseline ecrcl,26
480,baseline bmi nmbr to < nmbr kg / mnmbr  n = nmbr,26
1700,baseline diabetes,26
758,baseline killip class,26
1397,baseline cardiac biomarkers,26
1138,baseline : < nmbr . nmbr meq / l eos : > nmbr . nmbr or < nmbr . nmbr meq / l,26
1889,baseline hbanmbrc,26
775,normoalbuminuria at baseline ( nmbr % of patients treated ),26
440,baseline albumin / creatinine ratio in nmbr classes,26
1096,baseline sgrq score,26
531,baseline ldl cholesterol,26
885,baseline copd exacerbation history  * n ( % ),26
1070,baseline ezetimibe usec,26
585,baseline pulmonary medication  n ( % ),26
1461,baseline statin usec,26
342,baseline ics use  n ( % ),26
1790,baseline post - bronchodilator % predicted fev  > nmbr % and no concurrent tiotropium,26
370,baseline heart rate,26
943,baseline disease and quality - of - life scores,26
1846,baseline triglycerides in nmbr classes,26
838,baseline fpg ,26
1003,baseline systolic bp,26
641,baseline post - bronchodilator % predicted fev  < nmbr %,26
1490,baseline hematocrit  median ( iqr ),26
996,baseline scales  median ( range ),26
701,baseline heart failure severity nyha class i,26
1786,baseline therapy,26
990,baseline cardiac biomarkers elevated,26
1516,hbanmbrc at baseline  %,26
1289,baseline median ( iq range ),26
319,baseline / concomitant therapies,26
1991,baseline crp ( mg / dl ),26
1309,baseline nihss score  median ( range ),26
1311,baseline cardiovascular medication  c n ( % ),26
1632,baseline tobacco use,26
250,baseline fev  ( l ),26
1480,baseline corticosteroids *,26
638,baseline medical therapy,26
1033,baseline nihss score ( % ) #,26
1377,baseline hb < nmbr g nmbr nmbr n = nmbr,26
44,baseline mean ( sd )  % [mmol / mol],26
1474,baseline sitosterol,26
1773,baseline ( geometric mean  cv ),26
626,baseline fvc  l,26
1941,no baseline corticosteroids,26
1226,baseline lp ( a ) in nmbr classes,26
41,st - elevation mi,25
1730,st - segment elevation mi,25
1259,nmbr - nmbr / week,24
1887,< nmbr % predicted arr ( n = nmbr  nmbr ),24
1336,( nmbr % ell ' ll  * non - hdl - c,24
497,nmbr - nmbr ( n = nmbr  nmbr ),24
1814,nmbr placebo ( n = nmbr nmbr ),24
1718,> nmbr . nmbr hdl cholesterol level,24
850,eze / simva nmbr / nmbr mg ( n = nmbr ),24
410,nmbr to < nmbr . nmbr %,24
318,at least nmbr severe flare,24
684,> nmbr . nmbrmmol / l ( n = nmbr ),24
1886,> nmbr years eze / simva baseline ldl - c,24
1362,nmbr year or more,24
1196,hbanmbrc nmbr % - < nmbr % ( n - nmbr ),24
1960,| interactior nmbr p,24
1971,nmbr / nmbr  nmbr ( nmbr . nmbr ),24
1320,nmbr placebo n = nmbr,24
50,nmbr mg / kg ( n = nmbr ),24
825,> nmbr yr warfarin experience,24
849,hbanmbrc nmbr - < = nmbr %,24
421,sita nmbr + pio nmbr,24
483,tertile nmbr ( nmbr . nmbr - nmbr . nmbr pg / ml ) n = nmbr,24
1962,eze / simva nmbr / nmbr mg n = nmbr,24
864,> nmbr servings / wk ( n = nmbr ),24
476,> nmbr % stenosis of coronary  carotid  or lower extremity arteries,24
1225,nmbr - nmbr . nmbr kg / mnmbr,24
1272,nmbr prolonged antithrombotic pretreatment ( n = nmbr ),24
1222,> nmbr days warfarin,24
1803,nmbr . nmbr - nmbr . nmbr kg / mnmbr,24
1275,nmbr locf ),24
1750,after nmbr h,24
162,evenls per nmbr  nmbr palienl - years,24
1808,> nmbr . nmbr pmol / liter hscrp level,24
40,nmbr to < nmbr kg / mnmbr,24
823,nmbr  nmbr / nmbr  nmbr ( nmbr . nmbr ),24
299,nmbr mg clopidogrel load,24
337,< nmbr . nmbr mmol / liter apob : apoa - l ratio,24
1787,hbanmbrc nmbr . nmbr to < nmbr . nmbr % ( nmbr - nmbr mmol / mol ),24
681,< nmbr . nmbr mmol / liter triglyceride level,24
806,nmbr yr km % ( n ),24
530,nmbr bmi  kg / m,24
245,at least nmbr flare,24
795,< nmbr . nmbr mm hg diastolic blood pressure,24
532,llv wlalil nmbr statin,24
1008,nmbr ( fevnmbr < nmbr % pred ),24
1105,nmbr - h plasma glucose during ogtt ( mmol / l ),24
1661,tertile nmbr,24
1706,nmbr . nmbr - nmbr . nmbr ml / min / nmbr . nmbr mnmbr,24
1649,( nmbr % cl ) interaction,24
262,> nmbr to < nmbr egfr  ml / min / nmbr . nmbr mnmbr a,24
1933,hbanmbrc $ nmbr . nmbr % ( nmbr mmol / mol ),24
1879,dasnmbr - nmbr ( esr ),24
1589,nmbr - nmbr ( severe ),24
1697,( $ nmbr mg / dl [nmbr . nmbr mmol / l] ),24
1083,> nmbr ( ml ) additional angiography,24
552,nmbr = help needed  still independent,24
1687,< nmbr years eze / simva,24
1448,kim nmbr ( pg / ml ),24
150,nmbr % < hbanmbrc < = nmbr %,24
220,> nmbr additional cv risk factorsnmbr,24
796,nmbr mg cohort,24
1647,nmbr no . of events,24
1841,nmbr . nmbr ( nmbr nmbr . nmbr ),24
528,nmbr - h pmg ( mg / dl ),24
1419,< nmbr months  n ( % ),24
966,nmbr = minor symptoms  no limitations,24
598,( nmbr % ci] nmbr,24
1507,nmbr - aminosalicylates | | | |,24
671,nmbr - nmbr with cv disease ( n = nmbr ),24
1710,nmbr vessels or left main,24
894,( nmbr % ci ) p value,24
98,> nmbr oral agents,24
933,> nmbr years education,24
975,> nmbr : obese class iii,24
667,> nmbr vessels with > nmbr % stenosis,24
1626,bmi kg - m - nmbr,23
1217,bmi ( kg / mnmbr ) < nmbr,23
1620,bmi ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ],23
1352,bmi ( nmbr . nmbr  nmbr . nmbr ),23
37,bmi > nmbr kg / mnmbr ( % ),23
177,bmi ( kg / mnmbr ) cardiac parameters,23
34,left ventricular ejection fraction  % af history,22
362,left ventricular ejection fraction within previous nmbr mo |,22
315,weight  median ( interquartile range )  kg,21
1472,weight ( range ) ( kg ),21
811,weight $ nmbr . nmbr kg  < nmbr . nmbr kg  n,21
33,weight ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ],21
615,continued thienopyridine n ( % ),20
32,continued thienopyridine n = nmbr subjects,20
630,not reported / unknown,19
31,non - q wave,19
742,not reported in ecrf,19
1905,non - drug - eluting stent,19
184,non - hdl - c in nmbr classes,19
1016,non - fatal myocardial infarction,19
1974,non - detectable / unknown  n ( % ),19
1223,non - hdl - c ( mmol / l  mean ),19
636,non - sulfonylurea secretagogues,19
974,non - study ppi use,19
553,non - metsyn,19
30,lesion length  mean ( sd )  mm,18
395,lesions bnmbr / c,18
29,percutaneous coronary intervention,17
1063,percutaneous coronary intervention or coronary artery bypass graft surgery  n ( % ),17
358,geographic region  %,16
575,geographic region - north america,16
1297,geographical region ( % ),16
27,geographic region - europe,16
24,receiving insulin therapy,15
815,receiving concomitant corticosteroids,15
1615,received an oral aha within nmbr weeks prior to screening,15
519,receiving concomitant nsaids and / or cox - nmbr inhibitors,15
1813,received > nmbr prior anti - tnf therapies  n,15
876,europe nmbr ( n = nmbr ),14
1820,europe  israel  or australia,14
1538,europe ( non - eu ),14
23,europe / lsrael,14
1117,hbanmbrc in patients with baseline hbanmbrc > nmbr % to < nmbr % ( > nmbr to < nmbr mmol / mol )  % [mmol / mol]  la  n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo subtracted change ( se ),13
1725,patients treated for > nmbr weeks ( % ),13
1116,patients with diabetic nephropathy,13
404,patients with > nmbr exacerbations resulting in hospital admission,13
576,all patients with fistulas ( n = nmbr ),13
1499,patients not receiving corticosteroids at baseline,13
1702,patient history of disease n ( % ),13
648,patients treated with insulin,13
1528,patients receiving corticosteroids at baseline,13
21,vents / patients,13
1488,patients with previous loss of response to and intolerance of infliximab *,13
1944,all patients with opg n - nmbr,13
1066,patient history of disease,13
431,patients without ra  as  or psa ( n = nmbr  nmbr ),13
18,number of ( % ) females,12
1906,number of exacerbations in the past nmbr months,12
1522,number of stents implanted,12
709,number of concomitant aeds  n ( % ),12
171,number omega - nmbr number placeb fatty acid,12
276,number of stent = nmbr,12
1109,number of antidiabetes drugs at screening  n ( % ),12
1961,number ( s ) of features present,12
1396,number of pack - years,12
1721,number of treated vessels ( per patient ),12
293,number ( % ) of patients with event,12
1701,number of vessels disease,12
438,number of exacerbations in last nmbr months ,12
877,number of subjects,12
1214,number of previous anti - tnf treatments for psoriatic arthritis,12
533,number of prior csdmards  n ( % ),12
1500,alteplase group ( n = nmbr ),11
15,alteplase ( n = nmbr ),11
77,acute coronary event,10
14,acute stent thrombosis,10
1262,acute and delayed reaction,10
976,acute dvt study,10
13,total invasive cancer,9
1690,total patients n = nmbr,9
234,total haq  nmbr - nmbr,9
38,total gadolinium - enhancing lesion count  no . ( % ),9
99,total chol  mg / dl,9
1186,total comparators  patients with events / total patients,9
372,total stent length,9
1574,total n = nmbr n ( % ),9
1334,total group ( n = nmbr ),9
10,apixaban vs . placebo,8
1301,apixaban,8
1510,apixaban  nmbr . nmbr mg,8
1966,p  net difference,7
439,p  all vs all,7
9,p  subgroup *,7
367,p - val . ( nmbr ),7
96,no p - blocker intake at randomisation ( n = nmbr ),7
1582,prior implantable cardiodefibrillator  n ( % ),6
644,prior use of biologic agents,6
7,prior percutaneous coronary intervention  n ( % ),6
65,prior years taking warfarin,6
443,prior use of biologics  n ( % ),6
1291,prior diabetes,6
1954,prior lipid - lowering agent use,6
639,prior corticosteroid failure only,6
281,no prior ml or stroke,6
195,prior stroke or transient ischemic attack,6
581,prior coronary revascularization  n ( % ),6
578,prior medications,6
1973,prior pacemaker  n ( % ),6
1031,prior ischemic stroke,6
872,no prior hf hospitalization ( n = nmbr  nmbr ),6
1843,prior disease,6
1233,prior immunnosupressive failure but no anti - tnf failure,6
718,prior congestive heart failure,6
146,prior cv event at randomization !,6
589,prior coronary artery bypass graft surgery,6
1040,prior carotid intervention,6
713,prior history of cardiovascular disease  n ( % ),6
1375,prior ml ( before index acs ),6
942,prior pci or cabg surgery,6
866,prior antihypertensive medication  n ( % ),6
1143,prior tnfi  n ( % ),6
1826,prior biologic exposure,6
561,prior coronary revascularization,6
1354,prior cerebrovascular disease,6
6,high intensity,5
172,high - intensity statin vs medium - or low - intensity statin at randomization,5
994,race  white  n ( % ),4
5,race and ss at baseline,4
812,race or ethnic group,4
271,race or ethnic group ( % ),4
1038,race / ethnicity  %,4
1551,race - non - white ( n = nmbr  nmbr ),4
396,death or stent thrombosis,3
950,death  mi  idr  or st,3
993,death  large mi,3
188,death or myocardial infarction,3
1056,death or absolute fvc decrease > nmbr %,3
4,death  mi  idr  st  or any timi bleeding,3
2,tofacitinib nmbr mg bid [n = nmbr |,2
287,tofacitinib nmbr mg two times a day,2
279,tofacitinib nmbr mg twice daily n = nmbr,2
1178,tofacitinib  nmbr mg ( n = nmbr ),2
1411,tnmbrdm duration ( years ),1
1,duration of hypertension  n ( % ),1
1160,duration of last qualifying episode of atrial fibrillation > nmbr days,1
903,duration of diabetes mellitus  y,1
1438,duration of ra ( years ),1
469,duration of psoriasis  years,1
1655,duration of tnmbrdm  y,1
1823,duration of hypercholesterolemia ( yr ),1
860,duration of tnmbrdm,1
242,duration of morning,1
1270,duration of hypertension ( years ),1
428,duration of ra ( time from symptom onset )  years,1
1199,duration  mean ( sd )  years,1
1242,duration of tnmbrdm ( % ),1
1678,duration of study - drug infusion,1
1825,heart failure or lvef < nmbr % associated with index acs event,0
0,heart failure ( class l - lll ),0
454,heart failure nyha ii - iii,0
321,heart failure criteria met,0
424,venous graft,-1
417,resection performed  %,-1
414,laboratory findings,-1
411,simvastatin monotherapy ( n = nmbr  nmbr * ),-1
399,neuropilin ( ng / ml ),-1
394,parenteral anticoagulalion before randomization,-1
1775,days without albuterol use  * %,-1
1776,treatment with open - label perindopril,-1
393,% stenosis  as assessed by investigator,-1
1315,double - vessel disease  n ( % ),-1
1778,arterial graft,-1
387,tirofiban ( n = nmbr ),-1
1780,time to treatment ( min ) t,-1
1781,serum potassium : < nmbr . nmbrmmol / l ( n = nmbr ),-1
384,aml / val nmbr / nmbr mg,-1
383,atv nmbr mg study protocol,-1
382,puerperium,-1
380,visits nmbrenmbr,-1
379,serum total cholesterol  mmol / l ( sd ),-1
419,ada ifg,-1
1767,medications at discharge or day nmbr  if earlier ( % ),-1
1788,history of recurrent venous thromboembolism,-1
460,anti - ischaemia agents *,-1
470,procedures for index event,-1
466,systolic blood pressure [mmhg] ( interaction : p = nmbr . nmbr ),-1
1751,fevnmbr % pred,-1
1752,copd assessment test ( cat ) score,-1
465,chd risk equivalents  n ( % ),-1
462,mycophenolate mofetil,-1
461,exposure,-1
458,factor xa inhibitor,-1
1766,syst . bp ( mmhg ),-1
451,abnormal angiogram,-1
447,pain in extremity,-1
1761,health assessment questionnaire - disability index,-1
435,age at diagnosis  y,-1
434,upper respiratory tract infection nmbr ( nmbr . nmbr ),-1
433,renin - angiotensin inhibitors,-1
429,grouped region,-1
377,lv mass index ( g / mnmbr - nmbr ),-1
1789,magnetic resonance angiography,-1
473,ct or mr scan of the brain *,-1
1810,calcium supplements,-1
1812,country : argentina ( n = nmbr ),-1
332,russia / georgia ( n = nmbr ),-1
326,coronary angiography and intervention,-1
325,rheumatic heart disease,-1
324,other nsaids,-1
323,pulmonary function tests  % of predicted,-1
314,systemic corticosteroid use,-1
313,european trial,-1
312,intravenous vasodilators ( % ),-1
306,medication adherence,-1
304,large mi,-1
1824,personal relationships,-1
302,telmisartan ( n = nmbr  nmbr ),-1
301,primary prevention subgroup,-1
1827,need for urgent coronary - artery bypass grafting,-1
297,galectin - nmbr ( ng / ml ),-1
295,infarct characteristics,-1
335,oxidative stress,-1
339,less than nmbr %,-1
376,mri substudy ( n = nmbr ),-1
343,bosentan ( n = nmbr ),-1
1791,id genotype,-1
375,non - stemi,-1
365,psoriatic arthritis pain],-1
361,prior biologic therapy ( including anti - tnfs ),-1
356,pav  mean ( nmbr % ci ),-1
355,serum hdl cholesterol ( mmol / l )  mean ( sd ),-1
353,symbol digit score,-1
349,low molecular weight ( lmw ) heparin before randomisation,-1
1799,asthma duration ( sd )  years,-1
1800,glucose metabolism,-1
1801,glycated hemoglobin  median ( iqr ),-1
348,psa duration  years,-1
347,other antiarrhythmics^,-1
346,third heart sound  n ( % ),-1
1805,rectum and sigmoid colon only,-1
345,left - sided disease only,-1
344,nitrates ( oral or topical ),-1
1748,medically important infectionsa,-1
475,indeterminate or unknown,-1
622,hispanic / latin american,-1
565,ml without st - segment elevation !,-1
590,c - peptide  median ( ql  qnmbr )  nmol / l,-1
1686,laba / lama,-1
573,elderly ( > nmbr years ),-1
569,contrast nephropathy risk score,-1
1689,o total randomized,-1
568,notable abnormalities,-1
566,hydralazine,-1
1692,lebrikizumab ( n = nmbr ),-1
555,level of renal impairment,-1
478,pulmonary disease,-1
554,hemoglobin  g nmbr nmbr,-1
550,permanent,-1
548,pef  post - bronchodilator  % predicted normal,-1
1698,very high risk,-1
547,safety population  n ( % ),-1
546,glargine,-1
545,device group,-1
544,coumadin,-1
593,missing data,-1
595,fastest third,-1
596,gemfibrozil,-1
1681,vitamin k antagonist ( e . g . warfarin / coumarol ),-1
619,theophylline compound,-1
618,uric acid ( mg / dl ),-1
617,diarrhea,-1
616,disease - progression composite outcome !,-1
613,nasal polyps,-1
1669,dual antiplatelet,-1
1670,digitalis,-1
611,tnl ultrapositive > nmbr . nmbr pg / l  nmbr = nmbr,-1
610,antimalarials only,-1
609,no corticosteroid + no imm  n,-1
1674,intermediate ( nmbr ) ( n = nmbr  nmbr  nmbr % ),-1
608,valvular disease ( % ),-1
605,family history of coronary artery disease,-1
1677,haemodynamics and lv function,-1
601,minimum stent diameter,-1
1679,salmeterol nmbr gg bid,-1
599,incidence rate,-1
541,recent surgery or trauma,-1
540,dx at presentation  n ( % ),-1
538,current smoker : ex - smoker ( % ),-1
1726,immunomodulatory agents,-1
515,other asian,-1
1729,alcohol use ( > nmbr drink / wk ),-1
513,femoral neck,-1
510,ii - iv ( % ),-1
507,body mass  kg,-1
1733,treated hypertension :,-1
505,history of cardiac arrhythmia,-1
502,available baseline blood specimen n,-1
494,interleukin - nmbr ( ng / l ),-1
1737,intense physical activity,-1
489,nyha class iii or iv ( n = nmbr ),-1
1739,cholesterol absorption inhibitor ( ezetimibe ),-1
488,cardiac resynchronization therapy,-1
1741,nadroparin vs control,-1
482,evaluable for acrnmbr at week nmbr  n,-1
1743,coexisting conditions,-1
1744,characteristics of pulmonary embolism at inclusion,-1
516,measurements,-1
517,antithrombotic / coagulant,-1
536,heart disease risk factors,-1
1724,dlqi  nmbr - nmbr *,-1
1707,demographic characteristics,-1
529,phenytoin,-1
1709,subset of patients on metformin,-1
527,montelukast ( n = nmbr ),-1
1711,congenital shunts,-1
526,procedure,-1
1713,methotrexate dose at baseline,-1
524,i & ii : fevnmbr > nmbr % predicted,-1
1715,mesothelin ( ng / ml ),-1
1716,non - smoker ( n = nmbr  nmbr ),-1
1717,amlodipine / valsartan nmbr / nmbr mg / v = nmbr,-1
523,anti - inflammatory drugs,-1
1719,past or current angina pectoris,-1
1720,history of peripheral vascular disease,-1
520,b digit symbol substitution  omega - nmbr fatty acids vs placebo,-1
518,myocardial infarction within the previous nmbr yr,-1
1723,lipid - lowering therapy,-1
292,baseline dyspnea index  mean total score,-1
1831,alpha nmbr blockers,-1
1832,moderate dysfunction,-1
88,medication taken alone or in combination,-1
115,detemir / insulin glargine  %,-1
1940,overall quality of life,-1
113,haemorrhagic,-1
101,benralizumab nmbr mg qnmbrw ( n = nmbr ),-1
94,wml load at follow - up mri,-1
93,absolute  litres,-1
1945,urinary albumin : creatinine ratio ( pg / mg )  median ( iqr ),-1
91,bare metal stent  n ( % ),-1
87,angiotensin - converting enzyme inhibitors / angiotensin receptor blockers,-1
1833,tnf - rnmbra ( ng / ml ),-1
1949,nihss at randomization  nmbr - nmbr,-1
1950,cilostazol,-1
82,cardiovascular history,-1
80,dyspnoea - mmrc grade  n ( % ),-1
78,ntpro - cnp ( ng / ml ),-1
76,varespladib ( n = nmbr ),-1
75,implantable cardioverter - defibrillator,-1
1956,absolute change,-1
1938,titre ( u / ml ) t,-1
118,coronary revascularization nmbr days after randomization,-1
119,sacubitril / valsartan,-1
121,paracetamol,-1
1918,extreme tortuosity,-1
140,prior myocardial infarction,-1
137,health habits,-1
1921,geographic distribution - no . ( % ),-1
1922,conventional synthetic dmard use at baseline,-1
1923,at six weeks,-1
136,right coronary,-1
135,cholesterol  ( . nmbr . nmbr mmol / l )  n ( % ),-1
134,bypass surgery,-1
133,crude analysis  n ( % ),-1
132,metabolic syndromenmbr baseline lipids  mg / dl,-1
131,rasagiline  nmbr mg / day,-1
1930,third primary ( change in updrs score / wk  wk nmbr - nmbr ),-1
1931,implanted pacemaker,-1
130,toast classification of qualifying stroke,-1
127,draining cutaneous fistula at baseline  n ( % ),-1
1934,ret / abx - facil . pci,-1
69,invasive,-1
1958,low eosinophil subgroup (  nmbr / ml ) ( n = nmbr ),-1
1959,alaska native,-1
1980,deep - vein thrombosis ( % ),-1
1982,greater than or equal to nmbr ml / min / nmbr . nmbrmnmbr,-1
28,indian ( indian subcontinent ),-1
26,cyclosporine ( n = nmbr ),-1
25,abdominal or perianal fistula at baseline  n ( % ),-1
22,number of patients with,-1
20,argentina,-1
19,emphysema ( % ),-1
17,nmbrth - nmbrth percentiles,-1
1990,diagnosis of heterozygous familial hypercholester,-1
16,relative decrease > nmbr %,-1
12,subarachnoid hemorrhage,-1
11,second prior mi,-1
1994,other vasodilator,-1
1995,maintenance dose,-1
8,pre - randomization pci,-1
1997,perfusion defectsatinclusion,-1
3,temporary discontinuation of study drug,-1
1981,cardiovascu lar subg roup,-1
35,single - vessel disease  n ( % ),-1
67,latin america hr ( nmbr % cl ),-1
1978,pulse pressure,-1
66,bnp  median ( iqr )  pg / ml,-1
58,seizure types reported during baseline  n ( % ) a,-1
1963,bivalirudin,-1
1964,two arm,-1
1965,any blood pressure medications ( % ),-1
56,crcl at baseline < nmbr ml / min,-1
53,mepolizumab  nmbr mg ( n = nmbr ),-1
51,trend / het . test,-1
1969,calcium channel,-1
1970,no regular consumption,-1
48,secukinumab,-1
43,serum uric acid ( mg / dl ),-1
42,azathioprine ( n = nmbr ),-1
39,fatigue,-1
36,pad lower extremities,-1
1976,post - fibrinolysis angioplasty ( n = nmbr ),-1
1977,aerobic activity,-1
1917,irregular or ulcerated ica p ) laque : [ :,-1
144,diastolic blood pressure ( mm hg ) medications,-1
149,known duration of diabetes  yr,-1
253,severe dysfunction,-1
252,negative,-1
248,radial access,-1
247,lm bifurcation not treated,-1
1858,any new anti - hyperglycemic rx,-1
246,time to admission  min,-1
239,decreased appetite,-1
237,positive,-1
235,dipyridamole,-1
232,py = nmbr . nmbr ),-1
230,endothelin nmbr ( pg / ml ),-1
229,visit nmbr ldl cholesterol strata,-1
1866,ischemia on cecg ( n = nmbr  nmbr ),-1
1867,ularitide n / n ( % ),-1
227,psap - b ( ng / ml ),-1
1869,moderately high risk without atherosclerotic vascular disease *,-1
226,stool frequency subscore,-1
224,diabetes mellitus status,-1
1854,arterial blood pressure  mm hg,-1
255,aggressive ( n = nmbr ),-1
221,pancolitis,-1
256,aldosterone blocker  %,-1
1834,jejunum,-1
289,timi major / minor,-1
288,acpa positive  %,-1
285,oral medications,-1
284,anti - ccp antibody positive,-1
1839,diastolic fmmhff ' ),-1
278,nyha class nmbr - nmbr : no { n = llll ),-1
274,lev status  n ( % ),-1
1842,plaque score ( nmbr - nmbr ),-1
273,canakinumab,-1
272,dihydropyridine,-1
270,formoterol nmbr gg bid,-1
265,chondroitin sulfate ( n = nmbr ),-1
260,headache,-1
259,intraperitoneal,-1
1849,dronedarone ( n = nmbr ),-1
257,> nmbrmg / dl chd status,-1
222,death from any cause,-1
212,left ventricular hypertrophy ( % ),-1
154,gly nmbr . nmbr gg b . i . d n / n ( % ),-1
1895,symptoms of atrial fibrillation in the nmbr months before randomiza -,-1
1897,tiotropium / olodaterol nmbr / nmbr mg ( n = nmbr ),-1
180,grip strength ( kg ),-1
1899,rerapamil - sr strategy ( n = nmbr ),-1
179,blood urea nitrogen ( mg / dl ),-1
1901,valve surgery  n ( % ),-1
175,cigarette users,-1
169,diskus only  n,-1
1904,penetrating disease  %,-1
166,ethnicity ( % ),-1
165,intestinal area involved  n ( % ) $,-1
1907,potassium supplement,-1
1908,age group,-1
161,history of hyperlipidemia ( % ),-1
1910,platelet count  x nmbr mmnmbr,-1
1911,other supraventricular tachycardia,-1
160,cognitive functioning,-1
156,unfractionated heparin before randomisation,-1
1896,perindopril,-1
182,psychosocial risk factors,-1
1875,carotid artery diseaset,-1
183,bursitis,-1
211,calcium - channel blocker ( ratelowering ),-1
1877,daily activities,-1
210,physician ' s judgment that vka,-1
207,patent foramen ovale,-1
203,serious ae,-1
1881,traditional nsaid use,-1
202,full analysis set,-1
197,microvascular eye diseased,-1
1884,pro / pro homozygotes,-1
1885,sulfasalazine ( mean dose : nmbr . nmbr g / day ),-1
191,pain vas  nmbr - nmbr mm,-1
187,digital clubbing  n ( % ),-1
1888,pe associated with dvt at diagnosis,-1
185,family history ol diabetes ?,-1
1890,renal function < nmbr egfr  ml / min / nmbr . nmbr mnmbr,-1
1891,blood eosinophil concentration  nmbr cells per l,-1
1892,less severenmbr,-1
620,heterogeneity / trend test,-1
627,csf nmbrs - hydroxy -,-1
1310,scr  gmol / l,-1
1439,min  max,-1
1107,sglt - nmbr inhibitors^,-1
1104,only peripheral artery disease,-1
1433,control baseline ( n - nmbr ),-1
1102,heavy calcification,-1
1100,intent of early invasive strategy  %,-1
1436,fibrinolytic for qualifying event,-1
1095,thoracic cage fractures,-1
1094,vomiting,-1
1090,class l / ll heart failure,-1
1147,limb ( sd ),-1
1441,ctn - l  ng / ml,-1
1089,beta - adrenergic blocker,-1
1084,sbp < nmbr mmhg and dbp < nmbr mmhg,-1
1444,highest tg tertile,-1
1445,days of study - drug administration ( % ) * * nmbr day,-1
1082,dpp - nmbr inhibitor therapy,-1
1079,time from onset of pain to randomization  median ( iqr )  h,-1
1078,health state index score  uk algorithm,-1
1112,left anterior descending artery  n ( % ),-1
1113,albuterol reversibility  %,-1
1115,anyantianginal agent,-1
1427,des ( % previous stenting ),-1
1141,terminal ileum,-1
1136,elevated creatinine ( > nmbr pmol / l ),-1
1131,rosiglitazone,-1
1128,lp ( a )  mean ( sd ),-1
1414,gpiib / iiia receptor inhibitor,-1
1127,black race,-1
1416,supine after nmbr minutes change from baseline,-1
1126,ldl cholesterol at baseline ( mmol / l ) * ldl cholesterol at screening,-1
1123,subgroup by treatment interaction p - value,-1
1122,cardiac history  %,-1
1121,any cardiovascular disease history  n ( % ),-1
1421,right ventriculardysfunction atinclusion,-1
1422,micro - / macro - albuminuria  ckd and / or retinopathy,-1
1423,interaction : treatment by psoriasis p valuenmbr,-1
1119,risk factors  %,-1
1425,any aes  n ( % ),-1
1118,health - related quality of life,-1
1077,epa / aa ratio,-1
1075,triple - vessel disease  n ( % ),-1
1451,any immunosuppressive agent,-1
1025,left bundle - branch block,-1
1024,asia - pacific hr ( nmbr % cl ),-1
1021,aldosterone inhibitor,-1
1019,joint damage outcomes ( mitt population ),-1
1018,normal fasting glucose level ( n = nmbr ),-1
1478,arthritis,-1
1479,extensive,-1
1017,involved intestinal area  n ( % ),-1
1481,lv hypertrophy  n ( % ),-1
1012,carotid stenosis,-1
1007,emotional well - being,-1
1484,pain ( nmbr - nmbr mm vas ),-1
1005,mucolytic agent,-1
1004,angina class iii or iv prior myocardial infarction,-1
1002,hdl < nmbr / nmbr mg / dl ( nmbr . nmbr / nmbr . nmbr mmol / l ) for men / women,-1
999,thrombocytopenia,-1
998,tiotropium nmbr gg qd,-1
997,formal education  years,-1
1473,small vessel,-1
1034,free fatty acids ( mmol / l ),-1
1074,mixed chronic bronchitis and emphysema,-1
1037,angiogenin ( ng / ml ),-1
1453,increased waist circumference,-1
1454,cross - damp time : < l : llhrs : min ( n = nmbr ),-1
1072,mdi / hfa  n,-1
1068,mean platelet volume  fl,-1
1457,metrex overall modified intention - to - treat population ? :,-1
1458,cor revasc,-1
1061,tim nmbr nsk score,-1
1460,adl subscale ( range  nmbr - nmbr ) *,-1
1055,community hospital ( % ),-1
1462,enthesitis count,-1
1051,filtration rate nmbr - nmbr,-1
1464,history of alcohol use,-1
1047,baricitinib  nmbr mg daily ( n = nmbr ),-1
1466,female race / ethnicity,-1
1467,timing of clopidogrel loading dose,-1
1046,any relevant infarct,-1
1043,without dm ( n = nmbrinmbr * ),-1
1146,depressed and low perceived social support,-1
1148,emergent / urgent surgery,-1
635,single vessel coronary artery disease *,-1
1264,nationality,-1
1346,treatment duration  days,-1
1347,warfarin ( n = nmbr ),-1
1348,reported hypertension *,-1
1269,fibrin - specific,-1
1268,nicotine pack - years,-1
1267,biomarker status,-1
1266,history of paroxysmal atrial fibrillation  n ( % ),-1
1353,physical function ( nmbr - nmbr  short form - nmbr subscale ),-1
1258,certolizumab group ( n = nmbr ),-1
1149,laboratory measurements,-1
1255,vertebrobasilar infarct,-1
1251,pulse rate ( bpm ),-1
1358,haq - di score ( nmbr - nmbr ),-1
1248,medium - or low - intensity statin,-1
1247,medical history,-1
1241,salmeterol - fluticasone group,-1
1236,icd therapy vs . placebo no . hazard ratio ( nmbr . nmbr % cl ),-1
1363,three - vessel disease,-1
1345,intensive control,-1
1344,acute rheumatic disorders,-1
1343,osteoporosis,-1
1278,paclitaxel - eluting,-1
1306,ticlopidine ( n = nmbr ),-1
1326,hematologic,-1
1303,diabetic treatments !,-1
1328,ipf - related,-1
1300,thrombolytic treatment before randomization,-1
1298,serum haemoglobin anmbrc concentration ( % )  mean ( sd ),-1
1331,hba  % nmbrc,-1
1295,postoperative glucocorticoid use,-1
1333,hormone therapy,-1
1294,mean sgrq total score ( sd ),-1
1292,number of events / patients,-1
1290,pacific islander,-1
1287,circumflex,-1
1338,glomerular,-1
1286,pretreatment / concomitant treatment,-1
1279,distal anastomosis ( % ),-1
1341,balloon angioplasty plus abciximab,-1
1364,st - segment depression > nmbr . nmbr mv on admission  %,-1
1365,planned treatment duration  n ( % ),-1
1366,inadequate response / intolerance to prior therapy  %,-1
1188,angiotensin - converting enzyme inhibitor or angiotensin receptor blocker,-1
1389,tendonitis,-1
1179,tobacco use ( % ),-1
1391,oral contraceptives,-1
1392,anatomic complexity characteristics,-1
1175,spironolactone ( n = nmbr ),-1
1173,hormonal status,-1
1172,functional assessment of chronic illness,-1
1169,class i or iii aad use in nmbr months before enrollment,-1
1168,ejection fraction  % nyha class  n ( % ),-1
1166,additional investigations,-1
1399,diltiazem or verapamil,-1
1165,modmy al randcnxzaton,-1
1158,atherosclerosis^  n ( % ),-1
1402,bilateral disease ( % ) ' j ' ' j ',-1
1403,pathological q waves,-1
1404,leukocytes  nmbr / nl,-1
1405,lipid - lowering agents ( % ),-1
1181,history of congestive heart failure,-1
1192,permanently stopped study drug because of adverse events,-1
1231,anticoagulant therapy,-1
1194,metformin dose  mg,-1
1368,predominant type of heparin,-1
1369,western europe / australia / israel,-1
1229,south asian,-1
1228,dyspepsia,-1
1221,abrupt vessel closure,-1
1373,pulmonary embolism,-1
1220,history of bone disease ( predefined )  n ( % ),-1
1208,radius fracture,-1
1207,remission  n ( % ),-1
1206,genotyping,-1
1378,joint swelling,-1
1379,nmbrmwd decrease > nmbr m,-1
1380,profound thrombocytopenia ( < nmbrxnmbr / l ),-1
1205,denosumab ( n = nmbr ),-1
1201,intermittent claudication,-1
1383,peripheral edema,-1
1198,apremilast nmbr mg bid n = nmbr,-1
991,mental component score ( mcs ),-1
987,muscle spasms,-1
985,creatinine clearance by c - g ( ml / min ),-1
1608,current drinker,-1
1600,gusto - defined bleeding,-1
1601,peripheral vasodilators,-1
760,atrial flutter,-1
759,energy / fatigue,-1
1604,angiotensin - converting enzyme or angiotensin receptor blocker,-1
1605,perianal or anus,-1
1606,framingham nmbr - year cv risk score,-1
757,allhat - llt,-1
754,least square mean ( se ),-1
1494,documented asymptomatic cardiac ischemiac,-1
744,laba users,-1
1611,musculoskeletal,-1
741,hbanmbrc category  n ( % ),-1
733,opg  ( ng / ml ),-1
727,long - acting or short - acting nitrates,-1
725,coronary angiography during the index hospital stay,-1
1616,stiffness subscale,-1
724,enrollment in lmwh,-1
1599,repaired chd,-1
1598,das - nmbr ( crp ) < nmbr . nmbr  n ( % ),-1
1597,cad history and risk factors  n ( % ),-1
1596,upper gastrointestinal,-1
824,history of cardiovascular disease,-1
822,medications at randomization,-1
820,hyperkalemia ( > nmbr . nmbr meq / l ),-1
819,receptor blockers  n ( % ) baseline lipid and apolipoprotein levels,-1
810,no dysglycaemia or mets,-1
803,blood leukocyte count ( nmbr cells per l ),-1
802,hoehn and yahr stage ( range  nmbr - nmbr ),-1
799,smoking status at screening  n ( % ),-1
786,cardiac failure  n ( % ),-1
781,inflammatory disease,-1
778,rankin grade,-1
772,parental history of myocardial infarction before nmbr yr of age ( % ),-1
771,planned treatment strategy,-1
1592,history of percutaneous coronary intervention,-1
770,candesartan nmbr / nmbr,-1
761,subjects randomized,-1
1595,low - dose corticosteroid user,-1
720,diabetes therapy  n ( % ),-1
716,prasugrel,-1
712,glycemic drugs,-1
670,history of myocardial infarction ( % ),-1
1643,absolute risk difference ( ci )  % *,-1
1644,proctosigmoiditis,-1
669,losmapimod,-1
1646,cat total score,-1
663,cangrelor  %,-1
1648,intervention group ( n = nmbr ),-1
659,other countries,-1
1650,apoa - nmbr  g / l,-1
658,mets w / o tnmbrdm,-1
656,prior lipid - modifying therapy,-1
654,education  high school or higher,-1
1654,systemic glucocorticoid use at randomisation,-1
651,bdi total score ( baseline ),-1
650,iwqol - lite physical score ( arbitrary units ),-1
645,relative risk reduction ( nmbr % cl ),-1
643,crohn ' s disease activity index score],-1
1659,duration of crohn ' s disease ( yrs ),-1
1642,microalbuminuria or proteinuria,-1
672,severely impaired,-1
711,use nmbr - asa compounds,-1
674,anticyclic citrullinated peptide positive^  n ( % ),-1
708,glucose test,-1
706,low - molecular - weight,-1
1624,glycopyrronium nmbr mg ( n = nmbr ),-1
704,zotarolimus - eluting,-1
697,lumbar spine,-1
695,cancer ( n = nmbr ),-1
694,impaired fasting glucose level ( n = nmbr ),-1
693,neither pbo + statin eze + statin,-1
690,left ventricular ef  mean ( sd )  %,-1
1631,hospital factor # nmbr,-1
689,bronchitis,-1
1633,persistent anemia bsl hb < nmbrg i - nmbr  yr nmbr < nmbrg i nmbr,-1
1634,troponin t,-1
686,classification of af  no . ( % ),-1
675,wrist fracture,-1
1637,stroke risk score,-1
1638,daily insulin dose  mean ( sd )  iu,-1
826,intervention in complex lesions,-1
1577,orthostatic hypotension,-1
827,peak creatine kinase - mb  u / l,-1
954,ldl particle size ( week nmbr ),-1
951,unacceptable adverse events,-1
948,celecoxib ( n = nmbr ),-1
1518,history of intermittent claudication and abi < nmbr - nmbr or substantial peripheral arterial stenosis > nmbr %,-1
1519,months since ra was first diagnosed  mean ( sd ),-1
1520,hemorrhagic stroke ( n = nmbr ),-1
946,intended clopidogrel dose nmbr mg,-1
945,endoscopy subscore,-1
937,philippines,-1
936,mean blood pressure  mmhg ( s . d . j,-1
934,acute coronary syndrome nmbr,-1
927,very severe n z nmbr,-1
1527,% predicted pre - bronchodilator fevnmbr  % *,-1
924,sfnmbr - pcs,-1
923,creatinine  mean ( sd )  mg / dl,-1
910,prior cardiac surgery  n ( % ),-1
1531,general and lumbar epidural,-1
908,who / idf ifg,-1
952,tolal choleslerol - lo - hdl choleslerol ralio,-1
956,parameter,-1
905,total study population ( n = nmbr  nmbr ),-1
1512,vascular disease indicator no ( n = nmbr ),-1
983,family history of venous thromboembolism ( % ),-1
1496,disease location / type : terminal ileum,-1
982,vitamin e,-1
1498,clinical presentation,-1
981,rivastigmine ( n = nmbr ),-1
980,gallbladder - related aes,-1
973,any pulmonary medication,-1
1502,cardiac therapy  n ( % ) d,-1
970,biomarker low ( periostin < nmbr ng / ml or blood eosinophils < nmbr cells per pl )  na,-1
969,acc / aha lesion class bnmbr or c  n ( % ),-1
1505,apob : apoa - nmbr ratio,-1
1506,length of stay ( randomization to discharge  h ),-1
967,patients ' characteristics age ( years )  mean + sd,-1
1508,peripheral - artery disease ( % ),-1
1509,severity of the disease ( gold nmbr )  n ( % ),-1
964,cardiac rhythm,-1
1511,coronary bypass graft,-1
906,sita / pio nmbr / nmbr,-1
1535,diameter stenosis  mean ( sd )  %,-1
1575,chronic heart failure,-1
858,respiratory medication ( % ),-1
853,modified rankin scale score,-1
852,loop at last follow - up,-1
845,blood eosinophil count ( nmbr cells per l ),-1
1561,angina class at baseline,-1
843,western european includinq australia  israel  and south africa,-1
1563,albuminuria ( g / g ),-1
840,large - artery atherosclerosis,-1
835,int . p *,-1
1566,hdl cholesterol ( week nmbr ) a,-1
834,pancreatic cancer,-1
833,type of treatment  n ( % ),-1
832,angiotensin receptor blocker and / or ace,-1
831,leisure,-1
1571,menopausal status and use of hrt ( % ) y,-1
1572,renin inhibitor ( e . g . aliskerin ),-1
830,antithrombotic agents  n ( % ),-1
829,leflunomide ( mean dose : nmbr . nmbr mg / day ),-1
857,killip class,-1
1555,riva roxa ban n / n { % ) nmbr ( nmbr . nmbr ),-1
1536,biologic naive,-1
862,smoking status ( % ),-1
1537,systemic corticosteroids  n ( % ) a,-1
895,time from symptom onset to randomization,-1
1539,fasting blood glucose ( mg / dl ),-1
889,fish oil,-1
1541,rhabdomyolysis  myopathy  or myalgia with ck elevation > nmbrx uln,-1
887,blood pressure - lowering treatment,-1
886,european union,-1
882,control group ( n = nmbr ),-1
1545,phospholipid omega - nmbr levels : < nmbr % ( n = nmbr ),-1
880,pfo closure group ( n = nmbr ),-1
875,triple therapy use at screening  n ( % ),-1
871,open triple ( n = nmbr ),-1
1549,low hdl cholesterol,-1
870,smoking habit  n ( % ),-1
869,phosphorus  mmol nmbr nmbr,-1
868,standard therapy,-1
865,key secondary end point : st,-1
1999,disease activity outcomes ( itt population ) week nmbr,-1
